Treatment of Major Depression

Convergent molecular, cellular, and neural signatures of major depressive disorder

This study identifies convergent molecular, cellular, and neural signatures of major depressive disorder across multiple datasets and modalities.

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping

The paper develops a polygenic predictor for treatment-resistant depression using whole exome sequencing and genome-wide genotyping, finding that genetic scores combined with clinical factors improve prediction.

A preliminary study of brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination

This study examines cerebral metabolism changes in treatment-resistant depression patients before and after olanzapine-fluoxetine combination treatment, finding metabolism decreases in the amygdala correlate with clinical response.

Metabolic signature in nucleus accumbens for anti-depressant-like effects of acetyl-L-carnitine: An in vivo 1H-magnetic resonance spectroscopy study at 14 T

This study investigates the metabolic effects of acetyl-L-carnitine in the nucleus accumbens of stressed mice, showing normalization of energy-related metabolites in dominant mice.

Differential Treatment Benefit Prediction For Treatment Selection in Depression: A Deep Learning Analysis of STAR*D and CO-MED Data

The paper uses deep learning to predict differential treatment benefits for depression using STAR*D and CO-MED data, showing improved remission rates with model-guided treatment selection.

Light stimulation into dorsal raphe nucleus contributes to antidepressant effect for a stressed rat model

This study shows that light therapy alleviates depression-like behavior in stressed rats by modulating the retino-raphe circuitry and inhibiting 5-HT3A positive GABA cells in the dorsal raphe nucleus.

Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter, Stress Hormone, and Male Sex Hormone Systems

The paper develops a computational model of neurotransmitter and hormone systems to simulate neuroadaptation and screen drug combinations for improved antidepressant efficacy in males.

Machine learning identifies large-scale reward-related activity modulated by dopaminergic enhancement in major depression

The paper uses machine learning to analyze fMRI data and identifies reward-related brain activity changes in MDD patients after dopaminergic enhancement.

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment

This study identifies metabolomic clusters associated with depressive symptom change and treatment response to CBT in MDD patients.

Ovarian hormones mediate the prophylactic efficacy of (R,S)-ketamine and (2R,6R)-hydroxynorketamine in female mice

This study shows that (R,S)-ketamine and (2R,6R)-hydroxynorketamine prevent stress-induced depressive-like behavior in female mice, with ovarian hormones mediating their efficacy.

Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission.

This study shows that ketamine reduces RGS4 expression, disrupting neuromodulatory control of glutamatergic synapses in the prefrontal cortex of mice.

Venlafaxine stimulates PNN proteolysis and MMP-9 dependent enhancement of gamma power; relevance to antidepressant efficacy

This study shows venlafaxine reduces PNN integrity and increases gamma power via MMP-9 in mice, linking it to antidepressant effects.

Rapamycin, an Immunosuppressant and mTORC1 Inhibitor, Triples the antidepressant Response Rate of Ketamine at 2 Weeks Following Treatment: A double-blind, placebo-controlled, cross-over, randomized clinical trial

This study shows that pretreatment with rapamycin increases the antidepressant response rate of ketamine at 2 weeks but does not affect its acute effects.

Multi-OMIC analysis of brain and serum from chronically-stressed mice reveals network disruptions in purine metabolism, fatty acid beta-oxidation, and antioxidant activity that are reversed by antidepressant treatment

The paper analyzes multi-omic data from stressed mice to identify molecular disruptions linked to depression and shows antidepressants reverse these changes in specific brain regions.

Methylglyoxal modification of TrkB promotes synaptic plasticity and enhances resilience to chronic stress

This study shows that methylglyoxal (MGO) enhances resilience to chronic stress and alleviates depression-like symptoms by promoting synaptic plasticity through TrkB activation and BDNF expression.

THE ROLE OF DENDRITIC BRAIN-DERIVED NEUROTROPHIC FACTOR TRANSCRIPTS ON ALTERED INHIBITORY CIRCUITRY IN DEPRESSION

The paper investigates the role of BDNF transcript variants in altered inhibitory circuitry in depression by analyzing gene expression and behavioral changes in humans and mice.

Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: meta-analysis of three treatment cohorts.

This study evaluates polygenic risk scores for MDD and neuroticism as predictors of antidepressant response across three cohorts, finding no significant prediction but consistent directional effects.

Genome-wide translating mRNA analysis following ketamine reveals novel targets for antidepressant treatment

The paper uses RiboSeq to identify the translatome in mouse medial prefrontal cortex after ketamine treatment, revealing novel targets like VIPR2 for antidepressant action.

Exploring the prediction of emotional valence and pharmacologic effect across fMRI studies of antidepressants.

The paper uses fMRI data to predict emotional valence and pharmacologic effects of antidepressants, finding consistent emotional valence patterns but inconsistent drug-placebo discrimination.

Isoflurane produces antidepressant effects and induces TrkB signaling in rodents

This study shows that isoflurane anesthesia produces antidepressant-like effects in rodents by activating TrkB signaling and related molecular pathways.

Medial prefrontal cortical NMDA receptors regulate depression-like behavior and dictate limbic thalamus innervation

This study shows that deleting GluN2B from medial prefrontal cortex pyramidal neurons enhances synaptic activity and promotes antidepressant-like behavior in mice.

Pharmacogenetics of antidepressant response: a polygenic approach

This study investigates whether polygenic risk scores (PRS) can predict antidepressant response in MDD, finding no significant predictive effect.